Impact of early detection and steroid treatment on fetal ventricular heart rate and pacemaker implantation in anti-Ro/SSA positive congenital heart block.

IF 3.5 2区 医学 Q1 OBSTETRICS & GYNECOLOGY
Sven-Erik Sonesson, Aurelie Ambrosi, Felicia Nordenstam, Håkan Eliasson, Marie Wahren-Herlenius
{"title":"Impact of early detection and steroid treatment on fetal ventricular heart rate and pacemaker implantation in anti-Ro/SSA positive congenital heart block.","authors":"Sven-Erik Sonesson, Aurelie Ambrosi, Felicia Nordenstam, Håkan Eliasson, Marie Wahren-Herlenius","doi":"10.1111/aogs.14988","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>We investigated the effects of timing of detection and transplacental fluorinated steroid treatment on ventricular heart rate (HR) and age at pacemaker implantation in fetal third-degree atrioventricular block (AVB).</p><p><strong>Material and methods: </strong>Twenty-five of 31 fetuses diagnosed with Ro/SSA autoantibody-positive AVB II-III at our tertiary fetal cardiology center (2000-2020) and AVB III as final feto-neonatal outcome were reviewed.</p><p><strong>Results: </strong>AVB was detected approximately 5 weeks earlier in pregnancy if followed in a surveillance program compared to cases referred from primary care for bradycardia (20.6 [2.3] [mean (SD)] vs. 25.4 [3.2] weeks, p = 0.001). AVB detected before 24 weeks had higher HR than those detected later in gestation (63.3 [6.9] vs. 57.2 [6.9] bpm, p = 0.042), with a larger proportion having HR >60 bpm (80% vs. 33%, p = 0.041). The 17/25 cases that received treatment with fluorinated steroid were diagnosed earlier in gestation, with higher HR at diagnosis (61.7 [7.1] vs. 54.7 [6.3] bpm, p = 0.026), 1-2 weeks after diagnosis/treatment start, and before birth (65.4 [12.4] vs. 54.9 [5.7] bpm, p = 0.030) than untreated cases. Overall, 11 cases were commenced on betamimetics: three at diagnosis and eight at or after the examination made 1-2 weeks after diagnosis/treatment start, without any HR improvement. Two of 24 surviving babies were born preterm, and 4/24 received a neonatal pacemaker. Age at pacemaker implantation correlated significantly with HR before birth (Spearman R 0.57, p = 0.004), and fetuses with HR >60 bpm had a higher rate of pacemaker-free survival at three (90% vs. 40%, p = 0.018) and 12 months of age (80% vs. 13%, p = 0.002). The same trend was observed in pacemaker-free survival at 3 months of age in fluorinated steroid-treated compared to untreated cases (71% vs. 38%, ns).</p><p><strong>Conclusions: </strong>Our data confirm that AVB III detected earlier in gestation have a higher HR, and suggest that this higher HR can be successfully maintained to the end of gestation in cases treated with fluorinated steroids. Fetuses with HR >60 bpm before birth had a lower rate of pacemaker implantation at 3 and 12 months of age.</p>","PeriodicalId":6990,"journal":{"name":"Acta Obstetricia et Gynecologica Scandinavica","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Obstetricia et Gynecologica Scandinavica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/aogs.14988","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: We investigated the effects of timing of detection and transplacental fluorinated steroid treatment on ventricular heart rate (HR) and age at pacemaker implantation in fetal third-degree atrioventricular block (AVB).

Material and methods: Twenty-five of 31 fetuses diagnosed with Ro/SSA autoantibody-positive AVB II-III at our tertiary fetal cardiology center (2000-2020) and AVB III as final feto-neonatal outcome were reviewed.

Results: AVB was detected approximately 5 weeks earlier in pregnancy if followed in a surveillance program compared to cases referred from primary care for bradycardia (20.6 [2.3] [mean (SD)] vs. 25.4 [3.2] weeks, p = 0.001). AVB detected before 24 weeks had higher HR than those detected later in gestation (63.3 [6.9] vs. 57.2 [6.9] bpm, p = 0.042), with a larger proportion having HR >60 bpm (80% vs. 33%, p = 0.041). The 17/25 cases that received treatment with fluorinated steroid were diagnosed earlier in gestation, with higher HR at diagnosis (61.7 [7.1] vs. 54.7 [6.3] bpm, p = 0.026), 1-2 weeks after diagnosis/treatment start, and before birth (65.4 [12.4] vs. 54.9 [5.7] bpm, p = 0.030) than untreated cases. Overall, 11 cases were commenced on betamimetics: three at diagnosis and eight at or after the examination made 1-2 weeks after diagnosis/treatment start, without any HR improvement. Two of 24 surviving babies were born preterm, and 4/24 received a neonatal pacemaker. Age at pacemaker implantation correlated significantly with HR before birth (Spearman R 0.57, p = 0.004), and fetuses with HR >60 bpm had a higher rate of pacemaker-free survival at three (90% vs. 40%, p = 0.018) and 12 months of age (80% vs. 13%, p = 0.002). The same trend was observed in pacemaker-free survival at 3 months of age in fluorinated steroid-treated compared to untreated cases (71% vs. 38%, ns).

Conclusions: Our data confirm that AVB III detected earlier in gestation have a higher HR, and suggest that this higher HR can be successfully maintained to the end of gestation in cases treated with fluorinated steroids. Fetuses with HR >60 bpm before birth had a lower rate of pacemaker implantation at 3 and 12 months of age.

早期检测和类固醇治疗对抗Ro/SSA阳性先天性心脏传导阻滞的胎儿心室率和起搏器植入的影响。
简介:我们研究了胎儿三度房室传导阻滞(AVB)的检测时间和经胎盘氟化类固醇治疗对心室心率(HR)和起搏器植入年龄的影响:对我们的三级胎儿心脏病学中心(2000-2020 年)诊断为 Ro/SSA 自身抗体阳性二至三度房室传导阻滞(AVB II-III)的 31 个胎儿中的 25 个进行了回顾性研究:结果:与因心动过缓而从初级保健机构转诊的病例相比,如果在监测计划中进行随访,则房室传导阻滞的发现时间会提前约 5 周(20.6 [2.3] [平均值(标清)] 对 25.4 [3.2] 周,P = 0.001)。24 周前发现的房室传导阻滞患者的心率高于妊娠晚期发现的患者(63.3 [6.9] 对 57.2 [6.9] bpm,P = 0.042),心率大于 60 bpm 的患者比例更高(80% 对 33%,P = 0.041)。接受含氟类固醇治疗的 17/25 例病例在妊娠期诊断较早,诊断时(61.7 [7.1] vs. 54.7 [6.3] bpm,p = 0.026)、诊断/治疗开始后 1-2 周和分娩前(65.4 [12.4] vs. 54.9 [5.7] bpm,p = 0.030)的 HR 均高于未接受治疗的病例。总体而言,有 11 个病例开始使用倍他米特类药物:其中 3 例在诊断时使用,8 例在诊断/治疗开始后 1-2 周进行检查时或之后使用,但心率均无改善。24 名存活婴儿中有 2 名是早产儿,4/24 接受了新生儿心脏起搏器治疗。植入起搏器的年龄与出生前的心率有显著相关性(Spearman R 0.57,p = 0.004),心率大于 60 bpm 的胎儿在 3 个月(90% 对 40%,p = 0.018)和 12 个月(80% 对 13%,p = 0.002)时无起搏器的存活率较高。经含氟类固醇治疗的病例与未经治疗的病例相比,3个月大时无起搏器存活率呈相同趋势(71% vs. 38%,ns):我们的数据证实,在妊娠早期发现的 AVB III 具有较高的心率,并表明在使用含氟类固醇治疗的病例中,较高的心率可成功维持到妊娠结束。出生前心率大于 60 bpm 的胎儿在 3 个月和 12 个月大时植入起搏器的比例较低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.00
自引率
4.70%
发文量
180
审稿时长
3-6 weeks
期刊介绍: Published monthly, Acta Obstetricia et Gynecologica Scandinavica is an international journal dedicated to providing the very latest information on the results of both clinical, basic and translational research work related to all aspects of women’s health from around the globe. The journal regularly publishes commentaries, reviews, and original articles on a wide variety of topics including: gynecology, pregnancy, birth, female urology, gynecologic oncology, fertility and reproductive biology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信